H.C. Wainwright Stays Bullish on Wave Life Sciences After Company Regains Full Rights to Lead AATD Asset
H.C. Wainwright has reiterated a Buy rating on Wave Life Sciences (WVE) and set a $30.00 price target after the company recovered global rights to its RNA editing candidate WVE-006 from GlaxoSmithKline. The research firm points to a clearer regulatory path for alpha-1 antitrypsin deficiency (AATD) accelerated approval and notes additional analyst s…